Thymoma |
Cellular component | Expressed | Negative |
Neoplastic epithelial cells | - Keratin AE1/AE3, CAM 5.2, CK5/6, p40, p63
- PAX8 (100% type A, 93% type B thymomas using polyclonal antibody[1,2])
- CD20 (some type A, AB)
- Bcl-2 +/–
- TTF-1 (rare type A)[2]
| |
Thymocytes | - TdT (may be absent in type A and B3 thymoma)
| |
Thymic carcinoma |
Carcinoma subtype | Expressed | Negative |
Squamous cell carcinoma | - p40, p63, CK5/6
- CD5 +/–
- CD117 +/–
- PAX-8 (polyclonal)
| |
NUT carcinoma | - NUT
- p40, CK5/6 +/–
- TTF-1, CD34 +/–
- t[15;19] BRD4-NUT translocation; other translocations or fusions involving the NUT locus can occur
- Simple karyotype
| |
Low-grade papillary adenocarcinoma[3] | - CK7
- CK8
- EMA+
- BerEP4+
- CD5 +/–
- CEA +/–
- CD117 +/–
| - CK20
- CDX2
- Thyroglobulin
- Calcitonin
- TTF-1
- PAX8
|
Mucoepidermoid carcinoma[4] | | |
Enteric-type adenocarcinoma[3] | - CK20
- CDX2
- MUC2
- CK7 +/–
- CD5 +/–
| |
Adenocarcinoma, NOS[3] | - Pancytokeratin
- CD5 +/–
- CEA +/–
- CA19-9 +/–
- CK7 +/–
| |
Immunostains aiding in the distinction between thymic carcinoma and metastases[2,5] |
Immunostain; % positive cases | Thymic carcinoma | Metastases |
CD5 | 20 to 100 | 0 to 34* |
CD117 | 60 to 87 | 20 to 100¶ |
CD5 & CD117 | 54 to 65 | 0Δ |
CD205 | 52 to 76 | 4 to 27 |
FoxN1 | 59 | 13 |
PAX8 | 0 to 80◊ | 0 to 33Δ◊ |
PAX8 & CD117 | 69 | 0 |
PAX8 & CD5 | 46 | 0 |